Company Overview and News

 
AstraZeneca Pharma India Limited - Shareholders meeting

2018-09-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ASTRAZEN 506820

 
AstraZeneca Pharma shares zoom nearly 11%

2018-08-17 thehindubusinessline
Shares of AstraZeneca Pharma India today surged nearly 11 per cent after the company received permission from the Drug Controller General of India (DCGI) to import and market olaparib tablets used for the treatment of ovarian and breast cancer.
ASTRAZEN 506820

 
An evening walk down Dalal Street | Sensex fails to hold 38,000, Nifty posts record close

2018-08-17 moneycontrol
The market ended a truncated week on a good note, as benchmark indices closed with strong gains. The Nifty ended the day at a record closing high, while the Sensex ended higher by almost 300 points. Having said that, it failed to hold 38,000-mark.
HINDALCO SAUKF 533262 VEDL SAUA AKLD HNDNF SAUD SAIL 500470 RAMKY TTST TATASTEEL TATLY IONEXCHANG 500113 500477 500214 ASTRAZEN 506820 AKLS 500440 ASHOKLEY

 
AstraZeneca Pharma India gets DCGI nod to market cancer drug in India

2018-08-16 moneycontrol
Drug firm AstraZeneca Pharma India today said it has received permission from the Drug Controller General of India (DCGI) to import and market olaparib tablets used for the treatment of ovarian and breast cancer.
ASTRAZEN 506820

 
AstraZeneca Pharma India Limited - Press Release

2018-08-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ASTRAZEN 506820

 
AstraZeneca gets nod to launch cancer drug

2018-06-21 thehindubusinessline
AstraZeneca Pharma India on Friday said that it has received approval from the Drug Controller General of India to market Durvalumab, a cancer treatment medicine. The nod paves the way for it to launch the product in the country. Durvalumab is indicated as a treatment option for patients with locally-advanced, unresectable non-small cell lung cancer and metastatic urothelial carcinoma. Shareholders will closely monitor the development.
JINDALSAW 500378 ASTRAZEN 506820

 
AstraZeneca gets marketing permission for cancer drug in India

2018-06-21 moneycontrol
AstraZeneca Pharma India today said it has received approval from the Indian drug regulator to market Durvalumab, a cancer treatment medicine, in the country.
ASTRAZEN 506820

 
AstraZeneca Pharma India Limited - Press Release

2018-06-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ASTRAZEN 506820

 
AstraZeneca Pharma India Limited - Spurt in Volume

2018-06-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ASTRAZEN 506820

 
AstraZeneca Pharma India Limited - Spurt in Volume

2018-06-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ASTRAZEN 506820

 
AstraZeneca Pharma India Limited - Clarification - Financial Results

2018-05-22 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ASTRAZEN 506820

 
AstraZeneca Pharma India Limited - Outcome of Board Meeting

2018-05-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ASTRAZEN 506820

 
AstraZeneca Pharma India Limited - Financial Result Updates

2018-05-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ASTRAZEN 506820

 
Four cos added to MSCI India index

2018-05-15 moneycontrol
As many as four companies - Avenue Supermarts, Biocon, HDFC Standard Life Insurance Company and InterGlobe Aviation - will be added to the MSCI India Index with effect from June 1. The news triggered buying in most of these companies, with shares of Avenue Supermarts surging 6.5 percent to Rs 1,516.80 on BSE.
BALRAMCHIN PWQFY INDIANB INDIGO 532814 532810 539448 539437 PFC IDFCBANK 500038 ASTRAZEN 506820

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to NSE:ASTRAZEN / ASTRAZENECA PHARMA INDIA LTD. on message board site Silicon Investor.

AZN: AstraZeneca PLC AZN: AstraZeneca PLC AZN: AstraZeneca PLC